Note 2 - Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2026

	*For the Three Months Ended March 31,*
	*2026*									*2025*
	*Cardiac Electrophysiology*			*Private Aviation*			*Total*			*Total*
Revenues:
Product revenue
VIVO	$	73		$	—		$	73		$	15
LockeT		175			—			175			128
Total product revenues		248			—			248			143

Service revenue, net
Luxe		—			42			42			—
Hops		—			142			142			—
Total service revenues, net		—			184			184			—
Total revenues		248			184			432			143

Less:
Cost of revenues:
Cost of product revenue		31			—			31			11
Cost of service revenues		—			11			11			—
Total cost of revenues		31			11			42			11

Acquired in-process research and development expense		—			—			—			119
Depreciation and amortization expense		367			37			404			531
Stock-based compensation expense		64			—			64			91
Salaries and benefits expense		810			5			815			1,314
Professional fees		514			142			656			727
Research and development expense		149			—			149			103
Interest income		(2	)		—			(2	)		(18	)
Interest expense		103			16			119			49
Change in fair value of royalties payable due to related parties		—			—			—			1,163
Change in fair value of minority equity interest		2,302			—			2,302			—
Change in fair value of deferred consideration		(2,877	)		—			(2,877	)		—
Income tax benefit		(175	)		—			(175	)		(724	)
Other segment items (1)		520			105			625			822
Segment net loss		(1,558	)		(132	)		(1,690	)		(4,045	)

Reconciliation of net loss
Adjustments and reconciling items		—			—			—			—
Consolidated net loss	$	(1,558	)	$	(132	)	$	(1,690	)	$	(4,045	)

Fair Value, by Balance Sheet Grouping [Table Text Block]

			*March 31, 2026*
	*Total*		*Level 1*		*Level 2*		*Level 3*
Assets:
Cash Equivalents
Mutual funds	$	339	$	339	$	—	$	—
Money market funds		66		66		—		—
Total assets	$	405	$	405	$	—	$	—

Liabilities:
Royalties payable due to related parties	$	792	$	—	$	—	$	792
Deferred consideration		8,151		—		—		8,151
Convertible notes payable		298		—		—		298
Total liabilities	$	9,241	$	—	$	—	$	9,241

			*December 31, 2025*
	*Total*		*Level 1*		*Level 2*		*Level 3*
Assets:
Cash Equivalents
Money market funds	$	2	$	2	$	—	$	—
Total assets	$	2	$	2	$	—	$	—

Liabilities:
Royalties payable due to related parties	$	792	$	—	$	—	$	792
Convertible notes payable		298		—		—		298
Total liabilities	$	1,090	$	—	$	—	$	1,090

Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

		Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
	Royalties Payable due to Related Parties		Deferred Consideration			Convertible Notes Payable
Balance at January 1, 2026	$	792	$	—	$	298
Fair value at issuance		—		11,028		—
Change in fair value		—		(2,877)		—
Balance at March 31, 2026	$	792	$	8,151	$	298

		Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
		Royalties Payable due to Related Parties		Deferred Consideration		Convertible Notes Payable
Balance at January 1, 2025	$	9,213	$	—	$	—
Change in fair value		1,163		—		—
Balance at March 31, 2025	$	10,376	$	—	$	—

Schedule of Property, Plant and Equipment, Useful Life [Table Text Block]

Machinery and equipment			2 - 5 years
Computer hardware and software			1 - 5 years
LockeT animation video			3 years
VIVO DEMO/Clinical Systems			1-5 years

Disaggregation of Revenue [Table Text Block]

	*For the Three Months Ended March 31,*
	*2026*		*2025*
Revenue - Product
US	$	94	$	135
Europe		154		8
Total Revenue - Product		248		143

Revenue - Services
US		184		—
Europe		—		—
Total Revenue - Services	$	184	$	—

Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]

	*For the Three Months Ended March 31,*
	*2026*			*2025*
Deferred revenue, beginning of period	$	—		$	—
Deferred revenue assumed as part of acquisition (see Note 3)		171			—
Revenue recognized during the period related to amounts included in the deferred revenue assumed		(92	)		—
Revenue deferred, net of revenue recognized during the period		47			—
Deferred revenue, end of period	$	126		$	—

Royalties Payable [Member]

Notes Tables

Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]


Instrument	*Valuation Technique*	*Unobservable Input*	*Input Range*
Royalties payable due to related parties	Discounted future cash flows	Share price		19.5	%
Deferred consideration	If converted method	Discount for lack of marketability		20	%

- Definition

Tabular disclosure of segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26A

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

+ Details

Catheter Precision, Inc. 10-Q